AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30284506
Drug: Neither rTMS
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither rTMS nor constraint therapy (control group)
Trial: 25113835
Drug: SANGUINATE 80
RxNorm normalized name: sanguinarine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SANGUINATE 80 mg/kg
Trial: 25113835
Drug: SANGUINATE 120
RxNorm normalized name: sanguinarine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SANGUINATE 120 mg/kg
Trial: 25113835
Drug: SANGUINATE 160
RxNorm normalized name: sanguinarine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SANGUINATE 160 mg/kg
Trial: 19462324
Drug: GABA chocolate
RxNorm normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA chocolate (10 g with 28 mg GABA)
Trial: 8355039
Drug: Ethinylestradiol (EE2)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol (EE2) 50 micrograms administered 24 hours before chemotherapy (FAC)
Trial: 8355039
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) administered 24 hours before chemotherapy (FAC)
Trial: 3320135
Drug: Zinc cream
RxNorm normalized name: CARRINGTON MOISTURE BARRIER/ZINC CREAM
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc cream BP
Trial: 23486907
Drug: Spironolactone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (50 mg/day) plus placebo
Trial: 23486907
Drug: Spironolactone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (50 mg/day) plus hydrochlorothiazide (25 mg/day)
Trial: 23486907
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg/day) plus placebo
Trial: 23883613
Drug: Fully automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully automated closed-loop therapy (model predictive control algorithm directing insulin and 20% dextrose infusion based on FreeStyle Navigator continuous subcutaneous glucose values, n = 12)
Trial: 23883613
Drug: Local protocol
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local protocol with intravenous sliding-scale insulin (n = 12)
Trial: 23883613
Drug: Fully automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully automated closed-loop therapy
Trial: 23883613
Drug: Local protocol
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local protocol with intravenous sliding-scale insulin
Trial: 10998076
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement therapy (GHRT) for 18 months
Trial: 3546466
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg metaproterenol aerosol solution
Trial: 3546466
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metaproterenol aerosol solution
Trial: 3546466
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg metaproterenol aerosol solution
Trial: 3546466
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg metaproterenol aerosol solution (repeated)
Trial: 25128931
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (5 μg/min) without alpha-adrenergic blockade
Trial: 25128931
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (5 μg/min) with phentolamine-induced non-selective blockade
Trial: 23715032
Drug: Ketoconazole (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (600 mg)
Trial: 19020163
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 1.5% mepivacaine
Trial: 19020163
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 1% mepivacaine
Trial: 17121036
Drug: Jingui Shenqi
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jingui Shenqi Pill plus prednisone
Trial: 12936972
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/day once daily for 3 days (AZM-3)
Trial: 12936972
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/day once daily for 6 days (AZM-6)
Trial: 12936972
Drug: Amoxicillin-clavulanate (AMC)
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (AMC) 500-125 mg three times daily for 10 days
Trial: 10506596
Drug: PIXY321 (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIXY321 (375 microg/m(2) subcutaneously twice a day)
Trial: 1996435
Drug: Nifedipine 5
RxNorm normalized name: nifedipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 5 mg administered sublingually
Trial: 6436526
Drug: Lipid emulsion
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 9 g of phospholipids (PL) per day for 7 days.
Trial: 6436526
Drug: Lipid emulsion
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 12 g of phospholipids (PL) per day for 7 days.
Trial: 6436526
Drug: Glucose administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose administered alone as the sole source of nonprotein energy (glucose period).
Trial: 30322353
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (4-day course)
Trial: 30322353
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy (with or without steroids)
Trial: 15515655
Drug: Intravenous furosemid
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemid administration
Trial: 3281058
Drug: Diltiazem (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (8 mg/kg/d)
Trial: 31728632
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg aerosol furosemide
Trial: 16306801
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily for 4 weeks
Trial: 9616531
Drug: Metacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacholine inhalation test
Trial: 7630692
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of MPH
Trial: 7630692
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of MPH
Trial: 7630692
Drug: MPH (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH (both doses)
Trial: 31374471
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive behavioral therapy (CBT) program (UPLIFT, n = 20)
Trial: 25823738
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficient (< 20 ng/mL) in SWOG cohort
Trial: 25823738
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficient (< 10 ng/mL) in LYSA cohort
Trial: 23555035
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for mothers and infants, initiated at 14 weeks of pregnancy
Trial: 23555035
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for mothers and infants, initiated at 28 weeks of pregnancy (prior PMTCT recommendations)
Trial: 19275278
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (10 mg/kg/day)
Trial: 17067452
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant therapy alone (Control)
Trial: 11323580
Drug: Sequential ligation-sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential ligation-sclerotherapy (SLS)
Trial: 7965279
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg once a day
Trial: 3604959
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 3% NaBr solution (1 cc per kg body weight)
Trial: 3604959
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 3% NaBr solution (3 times over 6 weeks)
Trial: 10369626
Drug: Antiretroviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral agents (stavudine, lamivudine, saquinavir soft-gel capsules, nelfinavir, efavirenz)
Trial: 10369626
Drug: Azithromycin, cidofovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, cidofovir, famciclovir, valacyclovir, itraconazole suspension
Trial: 7771038
Drug: Automated thermo-infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated thermo-infusion dispenser with trental and actovegin for 120-hour infusion therapy
Trial: 30609983
Drug: Mobile phone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone-based telemedicine system with glucometers and advice on medication, diet, and exercise
Trial: 23932438
Drug: FDC solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC solifenacin 6 mg plus TOCAS 0.4 mg
Trial: 23932438
Drug: FDC solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC solifenacin 9 mg plus TOCAS 0.4 mg
Trial: 23932438
Drug: TOCAS 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOCAS 0.4 mg
Trial: 16703972
Drug: Random urine
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random urine drug testing
Trial: 8829019
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg once daily (increased to 400 mg twice daily if no improvement after 72 hours)
Trial: 8829019
Drug: Trimethoprim-sulfamethoxazole 960
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole 960 mg twice daily
Trial: 4046609
Drug: 3000 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 micrograms dihydrotestosterone (DHT) infusion
Trial: 4046609
Drug: 3000 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 micrograms estradiol (E2) infusion
Trial: 29795532
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with bupivacaine injection
Trial: 29795532
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with ropivacaine injection
Trial: 29795532
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without DPNB or PRB injection
Trial: 26739146
Drug: Best endovascular
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best endovascular treatment (angioplasty or stenting)
Trial: 22409379
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy in older patients
Trial: 22409379
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy in younger patients
Trial: 22409379
Drug: Drug reductions
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug reductions in older patients
Trial: 22409379
Drug: Drug reductions
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug reductions in younger patients
Trial: 19958075
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 or 300 mg/day
Trial: 19958075
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 or 300 mg/day)
Trial: 17907102
Drug: Candesartan cilexetil/hydrochlorothiazide
RxNorm normalized name: Candesartan Cilexetil/Hydrochlorothiazide 32 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil/hydrochlorothiazide (CC/HCTZ), 16 mg plus 12.5 mg
Trial: 18544707
Drug: Troglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone treatment
Trial: 10450339
Drug: Clonazepam treatment
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonazepam treatment for 10 days
Trial: 2135706
Drug: Nimodipine 30-60
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30-60 mg orally 2 hours prior to ECT
Trial: 27626518
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy without rituximab)
Trial: 20386260
Drug: STEPPS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEPPS plus an adjunctive individual therapy
Trial: 18353631
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy without chemotherapy
Trial: 15994714
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care (tobacco use treatment delivered by mental health providers)
Trial: 15994714
Drug: Usual standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual standard of care (cessation treatment delivered separately by smoking‐cessation specialists)
Trial: 12623832
Drug: Dorzolamide/timolol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol combination
Trial: 10100063
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg/day)
Trial: 6350409
Drug: Intranasal aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal aspirin (ASA) 22.5 mg per deciliter
Trial: 6350409
Drug: Intranasal aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal aspirin (ASA)
Trial: 6350409
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of ASA, Na salicylate, and indomethacin
Trial: 27756209
Drug: mDOT (mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mDOT (mobile directly observed therapy) with fixed dose hydroxyurea (HU) therapy and standard monitoring
Trial: 27756209
Drug: Standard monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monitoring (SM) with fixed dose hydroxyurea (HU) therapy
Trial: 17485707
Drug: Single autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single autologous stem-cell transplantation (ASCT) with high-dose melphalan at 200 mg/m2 (arm A)
Trial: 17485707
Drug: Double autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double autologous stem-cell transplantation (ASCT) with melphalan at 200 mg/m2 followed by melphalan at 120 mg/m2 and busulfan at 12 mg/kg (arm B)
Trial: 15172088
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (CE), 0.625 mg, and medroxyprogesterone acetate (MPA), 5 mg
Trial: 15172088
Drug: 17beta-estradiol (E2),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol (E2), 2 mg, and norethisterone acetate (NETA), 1 mg
Trial: 7911402
Drug: SCH 434
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 434 (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Trial: 7911402
Drug: CTM-D (chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTM-D (chlorpheniramine maleate 12 mg and pseudoephedrine sulfate 120 mg)
Trial: 28645982
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (nHF) therapy
Trial: 27928738
Drug: Vonoprazan 40
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 40 mg
Trial: 28198590
Drug: Vonoprazan 120
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 120 mg
Trial: 10079459
Drug: Self Psychological
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self Psychological Treatment (SPT)
Trial: 10079459
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation Treatment (COT)
Trial: 2285635
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg piretanide bid
Trial: 7137070
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (300 mg daily)
Trial: 15125213
Drug: Steroids combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids combined with thyroxine
Trial: 15125213
Drug: Steroids only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids only
Trial: 12207869
Drug: Carbatrol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbatrol (2 x 200 mg capsules), b.i.d. for 5 days
Trial: 12207869
Drug: Tegretol‐XR (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegretol‐XR (400 mg), b.i.d. for 5 days
Trial: 9427920
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus iontophoresis of calcitonin gene‐related peptide and vasoactive intestinal polypeptide
Trial: 9427920
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus placebo iontophoresis
Trial: 8085219
Drug: Fluoridated toothpicks
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated toothpicks (0.80 mg F as NaF)
Trial: 8085219
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg F tablet (Fludent)
Trial: 31559483
Drug: Optimization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization of medical therapy with sacubitril/valsartan, ivabradine, or both after CRT implantation
Trial: 29231603
Drug: Warm-needling moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm-needling moxibustion treatment for KOA, 40 min per treatment, 12 treatments over 3 weeks.
Trial: 29231603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for 3 weeks).
Trial: 29231603
Drug: Warm-needling moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm-needling moxibustion treatment for KOA.
Trial: 25957107
Drug: Taikong Yangxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taikong Yangxin (Chinese herbal medicine)
Trial: 23677418
Drug: Vaginal ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal ascorbic acid (250 mg tablets vaginally at bedtime once a day for 6 days, followed by one tablet per week for 12 weeks)
Trial: 11200381
Drug: Amoxicillin-clavulanate (ACA)
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (ACA) for 5 days
Trial: 11200381
Drug: Amoxicillin-clavulanate (ACA)
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (ACA) for 10 days
Trial: 11200381
Drug: Amoxicillin-clavulanate (ACA)
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (ACA) for 5 days and 10 days
Trial: 9311208
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol-fentanyl-ketamine (PFK)
Trial: 3596768
Drug: Hydrochlorothiazide (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25‐50 mg b.i.d.)
Trial: 3596768
Drug: Diltiazem (120‐180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120‐180 mg b.i.d.)